Principle of Assay
Human Bevacizumab/Avastin ELISA Kit (A326359) employs the sandwich enzyme immunoassay technique for the quantitative measurement of human Bevacizumab/Avastin in serum, plasma, cell culture supernatant, cell or tissue lysate, and other liquid samples. An antibody specific for Bevacizumab/Avastin has been pre-coated onto a 96-well microtiter plate. The standards and test samples are added into the wells and the Bevacizumab/Avastin present in each sample is bound to the wells by the immobilized antibody. Following incubation, the wells are washed and then incubated with Biotinylated Anti-Bevacizumab/Avastin Antibody, which binds the captured Bevacizumab/Avastin present in each well. Following incubation, unbound biotinylated detection antibody is removed by washing, and an HRP-Streptavidin conjugate is added to the wells and the microtiter plate is incubated. Following incubation and washing, TMB substrate solution is then used to visualize the HRP enzymatic reaction by catalysis to produce a blue-coloured product that changes to yellow after addition of acidic stop solution. The density of yellow is proportional to the amount of Bevacizumab/Avastin captured in each well. The concentration of Bevacizumab/Avastin can then be calculated by reading the O.D. absorbance at 450nm in a microplate reader and referring to the standard curve.
